View in EDS

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.

Saved in:
Bibliographic Details
Title: Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Authors: Bromberg, Jacoline E C1 (AUTHOR) j.bromberg@erasmusmc.nl, Issa, Samar2 (AUTHOR), Bakunina, Katerina3 (AUTHOR), Minnema, Monique C4 (AUTHOR), Seute, Tatjana5 (AUTHOR), Durian, Marc6 (AUTHOR), Cull, Gavin7,8 (AUTHOR), Schouten, Harry C9 (AUTHOR), Stevens, Wendy B C10 (AUTHOR), Zijlstra, Josee M11 (AUTHOR), Baars, Joke W12 (AUTHOR), Nijland, Marcel13 (AUTHOR), Mason, Kylie D14 (AUTHOR), Beeker, Aart15 (AUTHOR), van den Bent, Martin J1 (AUTHOR), Beijert, Max16 (AUTHOR), Gonzales, Michael17 (AUTHOR), de Jong, Daphne18,19 (AUTHOR), Doorduijn, Jeanette K20 (AUTHOR)
Source: Lancet Oncology. Feb2019, Vol. 20 Issue 2, p216-228. 13p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(18)30747-2